Search

Your search keyword '"Hawkes, Eliza A."' showing total 610 results
Start Over Author "Hawkes, Eliza A."
610 results on '"Hawkes, Eliza A."'

5. Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Author

Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., and Salles, Gilles

Published
2024
Full Text
View/download PDF

6. Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Author

Tobin, Joshua W. D., Chikatamarla, Venkata A., Matic, Marko, Griffin, Alison, Chowdhury, Rakin, Salvaris, Ross, Goh, Amanda, Black, Harrison, Tong, Tsz Hung, Birks, Callum, Jain, Sanjiv, Goodall, Elizabeth, Sirdesai, Shreerang, Trevis, Thomas, Steinepreis, Elizabeth, Chen, Yiyang, Li, Li, Broadby, Glenn, Gutta, Naadir, Morris, Kirk, Cochrane, Tara, Trotman, Judith, Talaulikar, Dipti, Shortt, Jake, Hodges, Georgina, Hawkes, Eliza A., Cheah, Chan Y., Barraclough, Allison, Manos, Kate, Johnston, Anna, Royle, Jane, Mondello, Patrizia, Ansell, Stephen M., and Hapgood, Greg

Published
2024
Full Text
View/download PDF

7. Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

Author

Lenton, Douglas, Taper, John, Presgrave, Peter, Butler, Jason, Mollee, Peter, Kannourakis, George, Steer, Christopher, Verner, Emma, Johnston, Amanda, Pati, Nalini, Hawkes, Eliza A., Lee, Hui-Peng, Cochrane, Tara, Cheah, Chan Yoon, Filshie, Robin, Purtill, Duncan, Sia, Hanlon, Enjeti, Anoop K., Brown, Christina, Murphy, Nicholas, Curnow, Jennifer, Lee, Kenneth, Gandhi, Maher K., Walia, Mannu, Butcher, Belinda E., and Trotman, Judith

Published
2024
Full Text
View/download PDF

9. Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Author

Manos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew, and Hawkes, Eliza A.

Published
2023
Full Text
View/download PDF

10. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Author

Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M., McKay, Pamela, Leitch, Sophie, Coleman, Morton, Zinzani, Pier Luigi, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Browett, Peter, Ke, Xiaoyan, Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, and Trotman, Judith

Published
2023
Full Text
View/download PDF

18. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma

Author

Wong, Jonathan, Gruber, Emily, Maher, Belinda, Waltham, Mark, Sabouri-Thompson, Zahra, Jong, Ian, Luong, Quinton, Levy, Sidney, Kumar, Beena, Brasacchio, Daniella, Jia, Wendy, So, Joan, Skinner, Hugh, Lewis, Alexander, Hogg, Simon J., Vervoort, Stephin, DiCorleto, Carmen, Uhe, Micheleine, Gamgee, Jeanette, Opat, Stephen, Gregory, Gareth P., Polekhina, Galina, Reynolds, John, Hawkes, Eliza A., Kailainathan, Gajan, Gasiorowski, Robin, Kats, Lev M., and Shortt, Jake

Published
2022
Full Text
View/download PDF

23. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort

Author

Martinez-Calle, Nicolas, Kirkwood, Amy A., Lamb, Maxine, Smith, Alex, Khwaja, Jahanzaib, Manos, Kate, Shrubsole, Caroline, Gray, Nicola, Lewis, Katharine, Tivey, Ann, Bishton, Mark J., Hawkes, Eliza, Ahearne, Matthew J., Osborne, Wendy, Collins, Graham P., Illidge, Timothy, Linton, Kim M., Cwynarski, Kate, Burton, Cathy, and Fox, Christopher P.

Published
2021
Full Text
View/download PDF

24. The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma.

Author

Barraclough, Allison, Lee, Sze Ting, Villa, Diego, Hapgood, Greg, Wilson, Don, Chong, Geoffrey, and Hawkes, Eliza A.

Subjects
FOLLICULAR lymphoma, POSITRON emission tomography, DIFFUSE large B-cell lymphomas, OVERALL survival, RADIOMICS
Abstract

Summary: Grade 3B follicular lymphoma (G3BFL) is a rare lymphoma thought to sit on a continuum between low‐grade FL and diffuse large B‐cell lymphoma (DLBCL). The prognostic impact of quantitative positron emission tomography (PET) metrics such as total metabolic tumour volume (TMTV), total lesion glycolysis (TLG), and maximum standard uptake value (SUVmax) have been extensively analysed in FL and DLBCL, but G3BFL data are lacking. Here, we describe PET outcomes and radiomic characteristics in 46 G3BFL cases uniformly treated with R‐CHOP (like) chemotherapy. Central semi‐automated PET TMTV, TLG, and SUVmax analyses, using MIM software, were correlated with clinical outcomes and compared with published results in low‐grade FL and DLBCL. In G3BFL, the end‐of‐treatment complete metabolic response was associated with improved progression‐free survival (PFS; p = 0.002) and overall survival (OS; p = 0.04). G3BFL median TLG (1455) and SUVmax (16.50) sit between published values for low‐grade FL (TLG: 1112, SUVmax: 11.3) and DLBCL (TLG: 3004, SUVmax: 24.35). No association between TMTV (>350 cm3) and survival was seen (PFS: p = 0.24; OS: p = 0.40). High SUVmax (>19.2) and TLG (>2760) both conferred inferior PFS but not OS (PFS: SUVmax p = 0.004; TLG p = 0.05). These data support the routine incorporation of PET radiomics at baseline and treatment response for G3BFL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Author

Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, and Nath, Karthik

Published
2024
Full Text
View/download PDF

26. Diffuse large B‐cell lymphoma.

Author

Barraclough, Allison, Hawkes, Eliza, Sehn, Laurie H., and Smith, Sonali M.

Subjects
BISPECIFIC antibodies, CHIMERIC antigen receptors, OLDER people, NEW trials, DOXORUBICIN
Abstract

Large B‐cell lymphoma, the prototype of aggressive non‐Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma‐related deaths. For nearly 4 decades, the goal of treatment has been "cure", first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and subsequently with rituximab plus CHOP. However, there is significant clinical, pathologic, and biologic heterogeneity, and not all patients are cured. Understanding and incorporating this biologic heterogeneity into treatment decisions unfortunately is not yet standard of care. Despite this gap, we now have significant advances in frontline, relapsed, and refractory settings. The POLARIX trial shows, for the first time, improved progression‐free survival in a prospective randomized phase 3 setting. In the relapsed and refractory settings, there are now many approved agents/regimens, and several bispecific antibodies poised to join the arsenal of options. While chimeric antigen receptor T‐cell therapy is discussed in detail elsewhere, it has quickly become an excellent option in the second‐line setting and beyond. Unfortunately, special populations such as older adults continue to have poor outcomes and be underrepresented in trials, although a new generation of trials aim to address this disparity. This brief review will highlight the key issues and advances that offer improved outcomes to an increasing portion of patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Women in Lymphoma: A 4‐year journey in promoting gender equity.

Author

Trotman, Judith, LaCasce, Ann, Osborne, Wendy, Steiner, Anna, Hawkes, Eliza, Casulo, Carla, Broussais, Florence, Cwynarksi, Kate, Ghione, Paola, Kahn, Justine, Kurtz, Sharyn, Linton, Kim, Mahuad, Carolina, Minnema, Monique, Nastoupil, Loretta, Pavlovsky, Astrid, Poon, Michelle, Sarkozy, Clémentine, Sehn, Laurie, and Smith, Soni

Subjects
DIFFUSE large B-cell lymphomas, GENDER nonconformity, LEADERSHIP in women, CORPORATE culture, SENIOR leadership teams, PEER review of students, PROSODIC analysis (Linguistics)
Published
2024
Full Text
View/download PDF

31. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Author

Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., and Salles, Gilles

Published
2020
Full Text
View/download PDF

32. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

Author

Tobin, Joshua W.D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi, Janowski, Wojt, Kridel, Robert, Cheah, Chan Y., MacManus, Michael, Matigian, Nicholas, Mollee, Peter, Gandhi, Maher K., and Hapgood, Greg

Published
2019
Full Text
View/download PDF

33. Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

Author

Verner, Emma, Johnston, Amanda, Pati, Nalini, Hawkes, Eliza A., Lee, Hui-Peng, Cochrane, Tara, Cheah, Chan Yoon, Filshie, Robin, Purtill, Duncan, Sia, Hanlon, Enjeti, Anoop K., Brown, Christina, Murphy, Nicholas, Curnow, Jennifer, Lee, Kenneth, Gandhi, Maher K., Walia, Mannu, Butcher, Belinda E., Trotman, Judith, Lenton, Douglas, Taper, John, Presgrave, Peter, Butler, Jason, Mollee, Peter, Kannourakis, George, and Steer, Christopher

Abstract

•Ibrutinib–R-mini-CHOP was a deliverable combination in patients with DLBCL aged ≥75 years.•Ibrutinib–R-mini-CHOP improves PFS compared with historical rates reported for R-mini-CHOP, but this study did not demonstrate a superior OS.

Published
2024
Full Text
View/download PDF

34. Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study.

Author

Lewis, Cameron S., Joy, Greta, Jensen, Paw, Barraclough, Allison, Franco, Nunzio, Talaulikar, Dipti, Hawkes, Eliza A., El‐Galaly, Tarec Christoffer, Villa, Diego, Dickinson, Michael, Seymour, John F., and Cheah, Chan Y.

Subjects
POSITRON emission tomography, HELICOBACTER pylori, END of treatment, OVERALL survival, LYMPHOMAS
Abstract

Summary: Primary gastric diffuse large B‐cell lymphoma (PG‐DLBCL) accounts for the majority of extra‐nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty‐seven eligible patients were identified. The median duration of follow‐up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4‐year progression‐free survival and overall survival of R‐CHOP was 88% (95% CI: 71–95) and 91% (95% CI: 75–97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R‐CHOP‐based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case‐by‐case basis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

Author

Tobin, Joshua W. D., Hapgood, Greg, Johnston, Anna, Cheah, Chan Y., Lee, Sze T., Trotman, Judith, Inam, Shafqat, Campbell, Belinda A., Norris, Debbie, MacManus, Michael, Hertzberg, Mark, and Hawkes, Eliza

Subjects
CONSENSUS (Social sciences), NON-Hodgkin's lymphoma, CANCER relapse, DISEASE management, MEDICAL societies, CHEMORADIOTHERAPY, DISEASE remission, TUMOR classification, EVIDENCE-based medicine, PATIENT aftercare, DISEASE progression
Abstract

Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma subtype, accounting for 15–20% of all lymphoma diagnoses. Although typically slow‐growing and responsive to frontline therapies, advanced‐stage FL remains incurable with current treatments and typically follows a chronic relapsing/remitting course with increasingly shorter responses to subsequent lines of therapy. Outcomes are highly variable; some patients experience prolonged first remissions that may approximate a 'functional cure'. By contrast, a significant minority of patients experience disease progression shortly after frontline treatment resulting in high rates of lymphoma‐related mortality. Reflecting on the heterogeneous natural history of FL, clinical practice varies widely, particularly in controversial areas, including appropriate disease staging, selection of management strategies and duration of clinical follow‐up. This position statement presents an evidence‐based synthesis of the literature for application in Australasian practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study.

Author

Manos, Kate, Churilov, Leonid, Grigg, Andrew, Di Ciaccio, Pietro, Wong, Jonathan, Chandra Sekaran, Usha, Wight, Joel, Goh, Zhong, Jina, Hayden, Butler, Llewyn, Yannakou, Costas K., Hamad, Nada, Gregory, Gareth P., Gangatharan, Shane, Cochrane, Tara, Hawkes, Eliza A., and Lasica, Masa

Subjects
NON-Hodgkin's lymphoma, HERPES simplex virus, LYMPHOMAS, OPPORTUNISTIC infections, MYCOSES
Abstract

Summary: Infection and lymphopenia are established bendamustine‐related complications. The relationship between lymphopenia severity and infection risk, and the role of antimicrobial prophylaxis, is not well described. This multicentre retrospective study analysed infection characteristics and antimicrobial prophylaxis in 302 bendamustine‐treated indolent non‐Hodgkin lymphoma patients. Lymphopenia (<1 × 109/L) was near universal and time to lymphocyte recovery correlated with cumulative bendamustine dose. No association between lymphopenia severity and duration with infection was observed. Infections occurred in 44% of patients (50% bacterial) with 27% hospitalised; 32% of infections occurred ≥3 months post bendamustine completion. Infection was associated with obinutuzumab and/or maintenance anti‐CD20 therapy, prior therapy and advanced stage. Twenty‐four opportunistic infections occurred in 21 patients: ten varicella zoster virus (VZV), seven herpes simplex virus (HSV), one cytomegalovirus, one progressive multifocal leucoencephalopathy, one nocardiosis, one Pneumocystis jiroveci pneumonia (PJP) and three other fungal infections. VZV/HSV and PJP prophylaxis were prescribed to 42% and 54% respectively. Fewer VZV/HSV infections occurred in patients receiving prophylaxis (HR 0.14, p = 0.061) while PJP prophylaxis was associated with reduced risk of bacterial infection (HR 0.48, p = 0.004). Our study demonstrates a significant infection risk regardless of lymphopenia severity and supports prophylaxis to mitigate the risk of early and delayed infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Author

Baggio, Diva, Chung, Eliza, Wellard, Cameron, Waters, Neil, Cushion, Tania, Chong, Geoffrey, Cochrane, Tara, Cull, Gavin, Giri, Pratyush, Hamad, Nada, Johnston, Anna, Lee, Denise, Murali, Aarya, Morgan, Susan, Mulligan, Stephen, Talaulikar, Dipti, Ratnasingam, Sumita, Wood, Erica, Hawkes, Eliza, and Opat, Stephen

Subjects
CHRONIC lymphocytic leukemia, RISK assessment, PROTEIN kinase inhibitors, PUBLIC health surveillance, RESEARCH funding, AGE distribution, REPORTING of diseases, DESCRIPTIVE statistics, CONFIDENCE intervals, SECONDARY primary cancer, PATIENT aftercare, PREVENTIVE health services, DISEASE risk factors, DISEASE complications
Abstract

Population‐based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age‐standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow‐up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

Author

Gleeson, Mary, Peckitt, Clare, To, Ye Mong, Edwards, Laurice, Oates, Jacqueline, Wotherspoon, Andrew, Attygalle, Ayoma D, Zerizer, Imene, Sharma, Bhupinder, Chua, Sue, Begum, Ruwaida, Chau, Ian, Johnson, Peter, Ardeshna, Kirit M, Hawkes, Eliza A, Macheta, Marian P, Collins, Graham P, Radford, John, Forbes, Adam, Hart, Alistair, Montoto, Silvia, McKay, Pamela, Benstead, Kim, Morley, Nicholas, Kalakonda, Nagesh, Hasan, Yasmin, Turner, Deborah, and Cunningham, David

Published
2018
Full Text
View/download PDF

47. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom

Author

Minson, Adrian, primary, Hamad, Nada, additional, Di Ciaccio, Pietro, additional, Talaulikar, Dipti, additional, Ku, Matthew, additional, Ratnasingam, Sumita, additional, Cheah, Chan, additional, Yannakou, Costas K., additional, Bishton, Mark, additional, Ng, Zi Yun, additional, Agrawal, Shivam, additional, McQuillan, Andrew, additional, Johnston, Anna, additional, Choong, Emily, additional, Wong, Kimberly, additional, McQuillan, James, additional, Beekman, Ashley, additional, Hawkes, Eliza, additional, and Dickinson, Michael, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results